Onglyza licence extended for use in combination with insulin

Onglyza (saxagliptin) can now be prescribed in combination with insulin for adults with type 2 diabetes, with or without metformin, when diet and exercise plus insulin alone do not provide adequate glycaemic control.

In a randomised, double-blind, placebo-controlled study (n=455), saxagliptin added to insulin therapy (with or without metformin) in patients with inadequate glycaemic control significantly reduced HbA1c and postprandial glucose levels compared with placebo at week 24. In an extension of the initial study, saxagliptin maintained the reduction in HbA1c levels at week 52 compared with placebo.

View Onglyza drug record

Further information: BMS/AstraZeneca

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in